Connect Biopharma (NASDAQ:CNTB) Earns “Buy” Rating from HC Wainwright

Connect Biopharma (NASDAQ:CNTB – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports.

Several other analysts have also recently weighed in on the company. Oppenheimer dropped their price objective on Connect Biopharma to $5.00 and set an “outperform” rating for the company in a report on Tuesday, September 22nd. Weiss Ratings lowered shares of Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. Wall Street Zen upgraded shares of Connect Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Leerink Partners assumed coverage on shares of Connect Biopharma in a research report on Monday, October 12th. They set an “outperform” rating and a $4.00 price target for the company. Finally, Canaccord Genuity Group dropped their price target on shares of Connect Biopharma from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, September 16th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $5.88.

Get Our Latest Research Report on CNTB

Connect Biopharma Stock Down 1.2%

NASDAQ CNTB opened at $0.84 on Wednesday. The stock has a fifty day moving average of $1.39 and a 200-day moving average of $2.20. The stock has a market capitalization of $52.61 million, a P/E ratio of -0.70 and a beta of -0.16. Connect Biopharma has a 52 week low of $0.73 and a 52 week high of $3.82. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.37 and a current ratio of 2.37.

Connect Biopharma (NASDAQ:CNTB – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.04. The firm had revenue of $2.75 million for the quarter, compared to analyst estimates of $0.74 million. On average, equities research analysts forecast that Connect Biopharma will post -1.09 EPS for the current year.

Institutional Investors Weigh In On Connect Biopharma

A number of institutional investors have recently made changes to their positions in CNTB. ADAR1 Capital Management LLC acquired a new position in Connect Biopharma in the first quarter valued at about $1,945,000. Bank of America Corp DE bought a new position in Connect Biopharma during the first quarter worth about $41,000. Knott David M Jr grew its position in shares of Connect Biopharma by 93.9% during the 1st quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after buying an additional 187,835 shares during the period. Finally, Simplify Asset Management Inc. acquired a new position in shares of Connect Biopharma during the 1st quarter worth about $135,000. 58.72% of the stock is owned by institutional investors and hedge funds.

About Connect Biopharma

(Get Free Report)

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases driven by T-cell activity. The company’s research programs target conditions in immunology, including inflammatory bowel disease, atopic dermatitis and other immune-mediated disorders.

Its pipeline has included rademikibart, formerly known as CBP-201, an investigational monoclonal antibody designed to block the interleukin-4 receptor alpha pathway, and ropsacitinib, formerly known as CBP-307, an investigational oral TYK2 inhibitor.

Further Reading

Analyst Recommendations for Connect Biopharma (NASDAQ:CNTB)

Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.